Keywords , MASH , GLP-1 receptor agonists , hepatic steatosis , metabolic dysfunction , tirzepatide , semaglutide , survodutide 0 2 INTRODUCTION Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), has emerged as the predominant hepatic pathology worldwide, impacting roughly twenty-five percent of the adult population [1,2]
Fortunately B12 shots are available
Hierarchical clustering analysis was performed to visualize relative differences in metabolite abundance between groups (Fig
When you stand up, gravity pulls CSF downward, slightly lowering intracranial pressure